Saturday 17 October 2026 Export SNN’s income statement to Excel — free account

Smith & Nephew SNATS, Inc.

Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024. Revenue growth for five consecutive years, operating cash flow growth for three.

29.06 0.03 −0.10%

Follow SNN

Alert me

Market cap: $12.2B
P/E: 35.4×
Fwd P/E: 18.6×
Dividend yield: 2.73%
F-score: 7/9
Altman Z: 3.49
Beneish M: −2.70
Dividend safety: 61/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 6.93%

Capital & Financial Ratios $m

Market Cap 12,170.00

Revenue 10,498.22

Net Income 2,019.00

Free Cash Flow 2,025.00

Net Debt 2,458.00

Current Ratio 2.14

Debt/Equity 0.62

P/E ratio 35.42

Fwd P/E 18.60

P/S ratio 1.24

P/B ratio 2.52

Past 5Y EPS Growth 7.02%

This Y EPS Growth 7.52%

Next Y EPS Growth 8.91%

Next Y revenue growth 38.03%

Next 5Y EPS Growth 9.41%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 80.61%

10-year low 10-year high

P/S against its own 10 years 21.93%

10-year low 10-year high

P/B against its own 10 years 25.54%

10-year low 10-year high

EV/Sales against its own 10 years 21.82%

10-year low 10-year high

EV/FCF against its own 10 years 1.36%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate 0.79

Annual Dividend Yield 2.73%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	0.53	0.48 0.31
2025	0.56	0.46 0.30
2024	0.75	0.46 0.29
2023	0.75	0.46 0.29
2022	0.75	0.46 0.29
2021	0.75	0.46 0.29
2020	0.75	0.46 0.29
2019	0.73	0.44 0.29
2018	0.73	0.45 0.28
2017	0.62	0.37 0.25
2016	0.63	0.38 0.25

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	302	619	557	754
Receivables	1,333	1,415	1,429	1,520
Inventory	2,395	2,387	2,117	2,113
Other	—	—	—	—
	4,030	4,421	4,103	4,387

	2023	2024	2025	Q'26
Payables	1,055	1,128	1,177	1,249
ST’ Debt	—	—	—	—
Other	451	340	268	229
	2,271	1,531	1,595	2,051

Compound Annual Growth %

	10y	5y	3y
Sales	2.89%	6.21%	5.73%
Cash Flow	2.24%	6.57%	40.03%
Earnings	4.31%	6.89%	40.99%
Book Value	2.92%	0.04%	0.19%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	6,164
’24	—	—	—	—	5,810
’23	—	—	—	—	5,549
’22	—	—	—	—	5,215
’21	—	—	—	—	5,212
’20	—	—	—	—	4,560

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	1,285
’24	—	—	—	—	987
’23	—	—	—	—	608
’22	—	—	—	—	468
’21	—	—	—	—	877
’20	—	—	—	—	935

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	260	—	—	—
’25	—	269	—	890	890
’24	—	66	—	606	606
’23	—	(54)	—	181	181
’22	—	34	—	110	110
’21	—	188	—	469	469
’20	—	(115)	—	492	492

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	1.43
’24	—	—	—	—	0.94
’23	—	—	—	—	0.60
’22	—	—	—	—	0.51
’21	—	—	—	—	1.20
’20	—	—	—	—	1.02

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	26.97	29.76	32.22	35.39	26.07	31.55	21.78	21.53	23.65	23.69	Analyst estimates 2026–2028 Powerpack
	High	35.38	40.43	39.85	48.93	52.26	46.10	36.68	33.09	31.72	38.79
People
People	Employees	15,644	15,933	16,377	17,637	18,000	18,000	19,012	18,452	17,349	16,988
	Revenue/emp, $m	0.30	0.30	0.30	0.29	0.25	0.29	0.27	0.30	0.33	0.36
Income, $m
Income, $m	Revenue	4,669	4,765	4,904	5,138	4,560	5,212	5,215	5,549	5,810	6,164
	Gross margin, %	72.76	73.81	73.53	73.96	69.39	70.40	70.47	68.82	69.64	68.01
	EBT	1,062	879	781	743	246	586	235	290	498	779
	EBT margin, %	22.75	18.45	15.93	14.46	5.39	11.24	4.51	5.23	8.57	12.64
	Net income	1,062	879	781	743	246	586	235	290	498	779
	Depreciation	463	447	435	502	562	567	617	683	645	573
Per share, $
Per share, $	Revenue	10.49	10.90	11.23	11.76	10.42	11.89	11.96	12.74	13.31	14.22
	Earnings	1.76	1.76	1.52	1.37	1.03	1.20	0.51	0.60	0.94	1.44
	Cash flow	1.91	2.49	2.13	2.67	2.14	2.00	1.07	1.40	2.26	2.96
	Capex	(0.88)	(0.86)	(0.79)	(0.93)	(1.01)	(0.93)	(0.82)	(0.98)	(0.87)	(0.91)
	Free cash flow	1.03	1.63	1.34	1.74	1.12	1.07	0.25	0.42	1.39	2.05
	Book value	8.89	10.63	11.17	11.76	12.07	12.70	12.06	11.98	12.06	12.20
	Shares, m	445	437	437	437	438	439	436	436	437	434
Valuation, ×
Valuation, ×	P/E	26.63	30.99	30.51	32.50	34.97	30.83	31.96	32.73	29.96	39.99
	P/S	2.92	3.40	2.81	2.43	1.92	1.58	1.19	1.15	1.05	1.40
	P/B	3.41	3.38	3.45	4.20	3.59	2.79	2.33	2.31	2.10	2.79
	EV/Sales	3.24	3.67	2.97	2.62	2.09	1.74	1.42	1.34	1.30	1.65
	EV/FCF	9.10	8.40	11.15	13.23	14.32	16.55	18.26	51.97	17.13	9.48
Cash, $m
Cash, $m	Operating cash flow	849	1,090	931	1,168	935	877	468	608	987	1,285
	Capex	(392)	(376)	(347)	(408)	(443)	(408)	(358)	(427)	(381)	(395)
	Free cash flow	457	714	584	760	492	469	110	181	606	890
Balance, $m
Balance, $m	Working capital	1,181	1,385	1,612	1,655	2,976	2,293	2,141	1,759	2,890	2,508
	Total debt	1,564	1,423	1,301	1,975	3,353	2,848	2,712	2,319	3,258	3,177
	Net debt	1,464	1,254	936	1,698	1,591	1,558	2,362	2,017	2,639	2,620
	Shareholders’ equity	3,958	4,644	4,874	5,141	5,279	5,568	5,259	5,217	5,265	5,289
Returns, %
Returns, %	ROA	10.81	10.09	8.33	6.91	4.41	4.78	2.14	2.64	4.05	6.01
	ROIC	9.23	9.90	9.28	7.45	2.68	5.20	3.69	3.67	5.20	6.27
	ROE	19.79	17.83	13.93	11.98	8.60	9.66	4.12	5.02	7.86	11.84

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2014

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ZBH Zimmer Biomet Holdings, Inc.	$18.0B	23.0×	17.7×	+4.80% (above 0%: growing)	+33.77% (above 0%: growing)	+13.05% (above 0%: growing)	70.81%	14.98%	Compare
PEN Penumbra, Inc.	$12.7B	78.4×	63.5×	+14.90% (above 0%: growing)	−24.79% (below 0%: shrinking)	+10.81% (above 0%: growing)	67.93%	10.52%	Compare
SNN Smith & Nephew SNATS, Inc.	$12.2B	35.4×	18.6×	+7.99% (above 0%: growing)	−14.23% (below 0%: shrinking)	+293.94% (above 0%: growing)	69.42%	0.00%
GMED Globus Medical, Inc.	$10.6B	19.3×	20.3×	+5.94% (above 0%: growing)	−25.33% (below 0%: shrinking)	+571.30% (above 0%: growing)	69.42%	23.10%	Compare
BIO.B Bio-Rad Laboratories, Inc.	$10.3B	43.7×	—	−0.09% (below 0%: shrinking)	+19.02% (above 0%: growing)	−6.06% (below 0%: shrinking)	53.12%	11.15%	Compare
GKOS Glaukos Corporation	$9.8B	— (loss-making)	— (loss-making)	+49.54% (above 0%: growing)	n/m	+211.83% (above 0%: growing)	81.67%	(9.30%)	Compare
BIO Bio-Rad Laboratories, Inc.	$9.8B	42.5×	35.4×	−0.09% (below 0%: shrinking)	+19.02% (above 0%: growing)	−6.06% (below 0%: shrinking)	53.12%	11.15%	Compare
PODD Insulet Corporation	$9.6B	26.4×	24.7×	+23.51% (above 0%: growing)	+328.13% (above 0%: growing)	−70.51% (below 0%: shrinking)	70.18%	16.18%	Compare
BRKR Bruker Corporation	$8.6B	— (loss-making)	55.7×	+5.15% (above 0%: growing)	n/m	+28.63% (above 0%: growing)	49.61%	(7.79%)	Compare
Median of peers	$10.0B	34.4×	30.0×	+5.55%	+19.02%	+11.93%	68.68%	11.15%

All 149 Medical Devices stocks →

Smith & Nephew SNATS, Inc. (SNN) key facts

Strength: Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024.
Strength: Net income was $779.0 million, or $1.44 per share (basic), a net margin of 10.1%.
Smith & Nephew SNATS, Inc. (SNN) is a Medical Devices company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, SNN traded at $29.06, a market capitalization of $12.2 billion.
At that price the stock trades at 35.4× trailing-twelve-month earnings and 1.2× sales; its P/E is higher than 81% of its own readings over the past ten years.
Smith & Nephew SNATS, Inc. pays an annual dividend of $0.79 per share, a yield of 2.73%.
Return on equity was 11.8% and debt-to-equity 0.62.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 3.49 (safe zone) for fiscal 2025.